Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRAF V600E is a determinant of sensitivity to proteasome inhibitors.

Molecular cancer therapeutics - 1 Dec 2013

Zecchin Davide, Boscaro Valentina, Medico Enzo, Barault Ludovic, Martini Miriam, Arena Sabrina, Cancelliere Carlotta, Bartolini Alice, Crowley Emily H, Bardelli Alberto, Gallicchio Margherita, Di Nicolantonio Federica

Abstract excerpt

A critical step toward defining tailored therapy in patients with cancer is the identification of genetic interactions that may impair-or boost-the efficacy of selected therapeutic approaches. Cell models able to recapitulate combinations of genetic aberrations are important to find drug-genotype interactions poorly affected by the heterogeneous genetics of human tumors. In order to identify novel pharmacogenomic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to 14-3-3 Proteins
Share to Drug Screening Assays, Antitumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Exoribonucleases

Share to Indoles

Share to Proteasome Inhibitors

Share to Sulfonamides

Share to Telomerase

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 24107445
DOI: 10.1158/1535-7163.MCT-13-0243

Genes

BRAF
PTEN
EGFR
KRAS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRAF V600E is a determinant of sensitivity to proteasome inhibitors.PMID 24107445Read ↗

Sensitivities and Dependencies of BRAF Mutant Colorectal Cancer Cell Lines with or without PIK3CA Mutations for Discovery of Vulnerabilities with Therapeutic Potential.Semantic proximity Read ↗

Cell line models for drug discovery in PIK3CA-mutated colorectal cancers.Semantic proximity Read ↗

Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.Semantic proximity Read ↗

The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targetsSemantic proximity Read ↗

Functional Characterization and Drug Response of Freshly Established Patient-Derived Tumor Models with CpG Island Methylator Phenotype.Semantic proximity Read ↗

Possibility of correlating mutational profile of cancer with drugs suitable for treatmentSemantic proximity Read ↗

Rationalizing Drug Response in Cancer Cell Lines.Semantic proximity Read ↗

Pro-Oncogenic c-Met/EGFR, Biomarker Signatures of the Tumor Microenvironment are Clinical and Therapy Response Prognosticators in Colorectal Cancer, and Therapeutic Targets of 3-Phenyl-2H-benzo[e][1,3]-Oxazine-2,4(3H)-Dione DerivativesSemantic proximity Read ↗

Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses.Semantic proximity Read ↗

Interactive webtool for analyzing drug sensitivity and resistance associated with genetic signatures of cancer cell lines.Semantic proximity Read ↗

Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies.Semantic proximity Read ↗

Identification of an "Exceptional Responder" Cell Line to MEK1 Inhibition: Clinical Implications for MEK-Targeted Therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.